

Amendments to the Claims:

The following listing of claims will replace all prior versions, and listings, of claims in this application.

Listing of claims:

1. (currently amended) A method for inhibiting macrophage death in a subject having, or at increased risk for developing, cardiovascular disease which comprises administering to the subject an ~~effective~~ amount of an ~~amphiphilic compound~~ amphipathic amine or a pharmaceutically acceptable salt thereof ~~which inhibits~~ effective to inhibit the intracellular transport of cholesterol within macrophage cells, ~~wherein the transport~~ is from an intracellular cholesterol storage site to the endoplasmic reticulum, so as to thereby inhibit macrophage death in the subject.
2. (currently amended) A method for inhibiting atherosclerotic lesional complications in a subject having, or at increased risk for developing, cardiovascular disease which comprises administering to the subject an ~~effective~~ amount of an ~~amphiphilic compound~~ amphipathic amine or a pharmaceutically acceptable salt thereof ~~which inhibits~~ effective to inhibit the intracellular transport of cholesterol within macrophage cells, ~~wherein the transport~~ is from an intracellular cholesterol storage site to the endoplasmic reticulum, so as to thereby inhibit atherosclerotic lesional complications in the subject.
3. - 26. (canceled)

27. (currently amended) A method for inhibiting atherosclerotic lesional necrosis[[,]] or plaque rupture ~~and/or superficial erosion~~ in a subject having, or at increased risk for developing, cardiovascular disease which comprises administering to the subject an ~~effective~~ amount of an ~~amphiphilic compound~~ amphipathic amine or a pharmaceutically acceptable salt thereof ~~which inhibits effective to inhibit~~ the intracellular transport of cholesterol within macrophage cells, ~~wherein the transport is~~ from an intracellular cholesterol storage site to the endoplasmic reticulum, so as to thereby inhibit atherosclerotic lesional necrosis[[,]] or plaque rupture ~~and/or superficial erosion~~ in the subject.

28.-49. (canceled)

50. (previously presented) The method of claim 1, wherein the ~~compound~~ amphipathic amine is 2 β -(2-diethylaminoethoxy)-androstenone (U18666A).

51. - 52. (canceled)

53. (previously presented) The method of claim 2, wherein the ~~compound~~ amphipathic amine is 2 β -(2-diethylaminoethoxy)-androstenone (U18666A).

54. - 61. (canceled)

62. (previously presented) The method of claim 27, wherein the ~~compound~~ amphipathic amine is 2 β -(2-diethylaminoethoxy)-androstenone (U18666A).

Applicant: Ira Tabas
Serial No: 10/767,749
Filed: January 28, 2004
Page: 5

63. - 64. (canceled)

65. (new) The method of claim 1, wherein the amphipathic amine is imipramine.

66. (new) The method of claim 2, wherein the amphipathic amine is imipramine.

67. (new) The method of claim 27, wherein the amphipathic amine is imipramine.